Rising triangle in anticipation of accelerated approval of FDAPharming has received acceptance from both the EMA and FDA for the accelerated review of leniolisib. The new drug is anticipated to generate significantly more revenue compared to its current profitable drug Ruconest. While the company has been profitable for the past years, it needed to find new so
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.014 CHF
−10.29 M CHF
258.32 M CHF
667.46 M
About PHARMING GROUP
Sector
Industry
CEO
Fabrice Chouraqui
Website
Headquarters
Leiden
Founded
2019
ISIN
NL0010391025
FIGI
BBG00LVF3SR1
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
Fading into PHARM negative trend.Pharming Group - 30d expiry- We look to Sell a break of 0.934 (stop at 0.993)
Short term bias has turned negative.
Daily signals are mildly bearish.
A higher correction is expected.
We are trading at overbought extremes.
0.936 has been pivotal.
A break of 0.936 is needed to confirm follow thr
PHARMING LONG after touched 200EMAPharming is a company with good fundamentals and now also available on the NASDAQ via a ADR (10 stocks). Take a look to the company.
Technical Analyse:
After it touched the 200 EMA you can see the big push to the North. My expectation is that this stock will go further North up, probably at least
PHARMING LONG termHello all,
Here another TA of me, this time on the stock PHARMING.
Its a very interesting company, i would advice you to dive in the fundamentals for further information. I will just show the possibilities with TA.
Before you choose to buy and hold a stock, always do your homework on the fundament
Pharming Group possible break of major resistance at 1.61Pharming group holdings has been hold back twice in history at around 1.6, i have been watching the MAC D and Stochastic indicator on the daily, they both show interesting signals such as on the macd: Descending red with ascending green, this would at least tell me a new attempt of breaking 1.61 is
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of PHGN is 0.778 CHF — it has decreased by −1.39% in the past 24 hours. Watch PHARMING GROUP NV stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange PHARMING GROUP NV stocks are traded under the ticker PHGN.
We've gathered analysts' opinions on PHARMING GROUP NV future price: according to them, PHGN price has a max estimate of 3.36 CHF and a min estimate of 1.30 CHF. Watch PHGN chart and read a more detailed PHARMING GROUP NV stock forecast: see what analysts think of PHARMING GROUP NV and suggest that you do with its stocks.
PHGN reached its all-time high on Mar 29, 2023 with the price of 1.242 CHF, and its all-time low was 0.657 CHF and was reached on Nov 27, 2024. View more price dynamics on PHGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PHGN stock is 1.41% volatile and has beta coefficient of 1.37. Track PHARMING GROUP NV stock price on the chart and check out the list of the most volatile stocks — is PHARMING GROUP NV there?
Today PHARMING GROUP NV has the market capitalization of 477.24 M, it has increased by 6.86% over the last week.
Yes, you can track PHARMING GROUP NV financials in yearly and quarterly reports right on TradingView.
PHARMING GROUP NV is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
PHGN earnings for the last quarter are 0.0045 CHF per share, whereas the estimation was 0.0017 CHF resulting in a 163.16% surprise. The estimated earnings for the next quarter are −0.0022 CHF per share. See more details about PHARMING GROUP NV earnings.
PHARMING GROUP NV revenue for the last quarter amounts to 84.19 M CHF, despite the estimated figure of 73.79 M CHF. In the next quarter, revenue is expected to reach 59.96 M CHF.
PHGN net income for the last quarter is 3.26 M CHF, while the quarter before that showed −888.10 K CHF of net income which accounts for 467.21% change. Track more PHARMING GROUP NV financial stats to get the full picture.
No, PHGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMING GROUP NV EBITDA is 343.09 K CHF, and current EBITDA margin is 2.48%. See more stats in PHARMING GROUP NV financial statements.
Like other stocks, PHGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMING GROUP NV stock right from TradingView charts — choose your broker and connect to your account.